Drug stops dangerous bleeding in patients taking factor Xa inhibitors

March 12, 2018 by Nicole Napoli, American College of Cardiology

The experimental drug andexanet was associated with control of serious bleeding in patients taking a common class of anticoagulants known as Factor Xa inhibitors, according to interim clinical trial results presented at the American College of Cardiology's 67th Annual Scientific Session. Millions of patients take Factor Xa inhibitors, which elevate the risk of serious bleeding. If approved by the FDA, andexanet would be the first agent available to directly reverse the effects of Factor Xa inhibition if bleeding occurs.

Factor Xa inhibitors, which inhibit a protein involved in the formation of blood clots, are commonly prescribed for who are at high risk for stroke and venous thrombosis (dangerous blood clots in the blood vessels). Because Factor Xa inhibitors and other anticoagulants reduce the body's ability to form a blood clot, these drugs can also increase the risk of uncontrolled bleeding. When this happens, it can be challenging for doctors to stop the bleeding and can ultimately lead to death. For example, about 25 percent of patients who experience bleeding in the brain while taking a Factor Xa inhibitor die.

"Unlike for some other anticoagulants, there is currently no approved reversal agent for Factor Xa inhibitors," said Stuart Connolly, MD, professor of medicine at McMaster University in Canada and the study's lead author. "Factor Xa inhibitors are already widely used because of their excellent efficacy and safety profile. However, some physicians and patients may choose to use other anticoagulant drugs because they have a reversal agent rather than using one of the Factor Xa inhibitors. Having a safe and effective reversal agent available will benefit patients with acute bleeding."

About 2.9 million people in the U.S. currently take Factor Xa inhibitors. Of these people, most are older and have illnesses, such as heart failure, that put them at high risk for cardiovascular problems. According to a recent analysis of the MarketScan Commercial and Medicare databases, roughly 84,000 patients taking Factor Xa inhibitors are hospitalized for major bleeding each year. The most common types of major bleeds include bleeding in the brain, sometimes resulting from a fall, and gastrointestinal bleeding.

Andexanet is a recombinant modified Factor Xa molecule designed to bind to and disable Factor Xa inhibitors, thereby allowing Factor Xa produced by the body to play its normal role in the formation of . In earlier trials performed in healthy volunteers, andexanet was shown to rapidly reverse the anticoagulant effect of Factor Xa inhibitors without any significant safety problems.

ANNEXA-4 is an ongoing clinical trial that uses andexanet to help treat patients experiencing major bleeding while taking Factor Xa inhibitors. The interim analysis being reported at ACC.18 includes data on safety outcomes for 227 patients and adjudicated efficacy outcomes for 132 patients enrolled at centers in the U.S., Canada and Europe. All trial participants presented with acute within 18 hours of taking one of four Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban or enoxaparin). Patients received an injection of andexanet followed by a two-hour infusion of the drug, with the dosage determined based on the specific Factor Xa inhibitor the patient was taking and how long it had been since the last dose.

The trial assesses the drug's efficacy in terms of two co-primary endpoints: reduction in anti-Factor Xa inhibitor activity and achievement of clinical hemostasis (stoppage of bleeding) by 12 hours after administration. The interim results show that median anti-Factor Xa inhibitor activity was reduced by 88 percent for patients taking rivaroxaban, 91 percent for patients taking apixaban and 75 percent for patients taking enoxaparin. Very few patients in the study had received edoxaban. Excellent or good clinical hemostasis was achieved in 83 percent of patients overall.

Safety of andexanet was assessed in all 227 patients. At 30 days, 12 percent of patients had died and 11 percent had a thrombotic event (stroke, heart attack or blood clot in the legs). According to Connolly, these rates of adverse events are in line with what would be expected given the underlying medical condition of the patients in the trial and the fact that many had not resumed anticoagulant treatment during the 30 days after receiving andexanet.

"This study is only focused on patients who are acutely bleeding, but there is also great interest in using a drug like andexanet for patients who come into a medical center on a Factor Xa inhibitor and require urgent surgery," Connolly said. "We hope to study that patient population in the future."

The study is not a randomized controlled trial and it does not include any patients who were not given andexanet (controls). Although a offers potentially stronger evidence than a single-arm study design, this method was deemed to be impractical because the drug is intended to be used during crisis situations, demanding a speed of response that could be difficult to achieve with randomization protocols.

Explore further: A rapid and effective antidote for anticoagulant bleeds

More information: The trial was funded by Portola Pharmaceuticals Inc., maker of andexanet.

Related Stories

A rapid and effective antidote for anticoagulant bleeds

August 30, 2016
A specially designed antidote to reverse acute, potentially life-threatening anticoagulant-related bleeding worked quickly, and was well-tolerated according to interim results of the ongoing ANNEXA-4 study.

Ticagrelor has comparable safety to clopidogrel after heart attack

March 12, 2018
Among people younger than 75 years who were given clot busters to treat a heart attack, taking the more potent blood thinner ticagrelor did not increase the risk of major bleeding (the primary endpoint) compared with the ...

Disruptive technology for the treatment of hemophilia

July 10, 2017
An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding ...

Study first to confirm effectiveness and safety of new treatment for hemophilia

November 2, 2011
An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events ...

Apixaban superior to warfarin across range of patient risk scores

October 1, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...

Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion

August 28, 2017
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented ...

Recommended for you

Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death

September 24, 2018
In the largest multi-institutional study to date, led by researchers from Penn Medicine, the team found that among patients who underwent a transcatheter aortic valve replacement (TAVR), a high number experienced severe and ...

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Can a common heart condition cause sudden death?

September 20, 2018
About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions ...

New drugs could reduce risk of heart disease when added to statins

September 20, 2018
New drugs that lower levels of triglycerides (a type of fat) in blood could further reduce the risk of heart attack when added to statins. These new drugs, which are in various stages of development, could also reduce blood ...

Mediterranean-style diet may lower women's stroke risk

September 20, 2018
Following a Mediterranean-style diet may reduce stroke risk in women over 40 but not in men—according to new research led by the University of East Anglia.

Inflammation critical for preventing heart attacks and strokes, study reveals

September 19, 2018
Inflammation, long considered a dangerous contributor to atherosclerosis, actually plays an important role in preventing heart attacks and strokes, new research from the University of Virginia School of Medicine reveals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.